Compare · NVO vs TARO
NVO vs TARO
Side-by-side comparison of Novo Nordisk A/S (NVO) and Taro Pharmaceutical Industries Ltd. (TARO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and TARO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $220.35B, about 122.3x TARO ($1.80B).
- NVO has hit the wire 5 times in the past 4 weeks while TARO has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 4 for TARO).
- Company
- Novo Nordisk A/S
- Taro Pharmaceutical Industries Ltd.
- Price
- $41.18+6.93%
- $42.97-0.02%
- Market cap
- $220.35B
- $1.80B
- 1M return
- +13.32%
- -
- 1Y return
- -34.24%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 4
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Taro Pharmaceutical Industries Ltd.
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest TARO
- SEC Form 15F-12B filed by Taro Pharmaceutical Industries Ltd.
- SEC Form 25-NSE filed by Taro Pharmaceutical Industries Ltd.
- Sun Pharma Completes Taro Merger
- Amendment: SEC Form SC 13D/A filed by Taro Pharmaceutical Industries Ltd.
- Amendment: SEC Form SC 13E3/A filed by Taro Pharmaceutical Industries Ltd.
- SEC Form 6-K filed by Taro Pharmaceutical Industries Ltd.
- SEC Form SC 13E3/A filed by Taro Pharmaceutical Industries Ltd. (Amendment)
- Sun Pharmaceutical And Taro Pharmaceutical Industries' Merger Agreement Was Approved By The Affirmative Vote Of Taro Shareholders
- Taro Shareholders Approve Merger with Sun Pharma
- SEC Form 6-K filed by Taro Pharmaceutical Industries Ltd.